Select Page

Are You CovidMune?™

Covid-19 Clinical Trials Sampling

This represents a sampling of the first 30 clinical trials listed on clinical trials.gov specific to cover-19 investigations. Twenty out of the thirty proposed trials has direct correlation to the protein NLRP3 with the drugs and treatments listed to be used in these studies.

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS)

https://clinicaltrials.gov/ct2/show/NCT04333407?cond=COVID-19&draw=3&rank=15

Condition or disease COVID-19

Drug: Aspirin 75mg – 940 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=aspirin+and+NLRP3

Drug: Clopidogrel 75mg – 140 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Clopidogrel+and+NLRP3

Drug: Rivaroxaban 2.5 MG – 22 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Rivaroxaban+and+NLRP3

Drug: Atorvastatin 40mg – 528 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Atorvastatin+and+NLRP3

Drug: Omeprazole 20mg – 74 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Omeprazole+and+NLRP3

Duvelisib to Combat COVID-19

https://clinicaltrials.gov/ct2/show/NCT04372602?cond=COVID-19&draw=2&rank=1

Condition or disease COVID-19

Drug: Duvelisib – 2 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Duvelisib+and+NLRP3

Application of Desferal to Treat COVID-19

https://clinicaltrials.gov/ct2/show/NCT04333550?cond=COVID-19&draw=2&rank=3

Condition or disease COVID-19

Drug: Deferoxamine – 135 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Deferoxamine+and+NLRP3

Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19

https://clinicaltrials.gov/ct2/show/NCT04336904?cond=COVID-19&draw=2&rank=4

Condition or disease COVID-19

Drug: Favipiravir – 19 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Favipiravir+and+NLRP3

Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression

https://clinicaltrials.gov/ct2/show/NCT04345445?cond=COVID-19&draw=2&rank=7

Condition or disease COVID-19

Drug: Tocilizumab – 307 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Tocilizumab+and+NLRP3

Drug: Methylprednisolone – 260 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Methylprednisolone+and+NLRP3

Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia

https://clinicaltrials.gov/ct2/show/NCT04359095?cond=COVID-19&draw=2&rank=8

Condition or disease COVID-19

Drug: Hydroxychloroquine – 254 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Hydroxychloroquine+and+NLRP3

Drug: Lopinavir Pill – 48 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Lopinavir+and+NLRP3

Drug: Ritonavir Pill – 75 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Ritonavir+and+NLRP3

Drug: Azithromycin – 206 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Azithromycin+and+NLRP3

Isotretinoin in Treatment of COVID-19 (Randomized)

https://clinicaltrials.gov/ct2/show/NCT04361422?cond=COVID-19&draw=2&rank=9

Condition or disease COVID-19

Drug: Isotretinoin – 44 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Isotretinoin+and+NLRP3

The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19

https://clinicaltrials.gov/ct2/show/NCT04347915?cond=COVID-19&draw=2&rank=13

Condition or disease COVID-19

Drug: Clevudine – 2 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Clevudine+and+NLRP3

Drug: Hydroxychloroquine – 254 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Hydroxychloroquine+and+NLRP3

Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection

https://clinicaltrials.gov/ct2/show/NCT04343183?cond=COVID-19&draw=2&rank=14

Condition or disease COVID-19

Device: Hyperbaric Oxygen Therapy – 169 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Hyperbaric+Oxygen+and+NLRP3

The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19

https://clinicaltrials.gov/ct2/show/NCT04291053?cond=COVID-19&draw=2&rank=17

Condition or disease COVID-19

Drug: Huaier Granule – 3 papers on NLRP3

https://www.ncbi.nlm.nih.gov/pmc/?term=Huaier+Granule+and+NLRP3

The Role of Resistant Starch in COVID-19 Infection 

https://clinicaltrials.gov/ct2/show/NCT04342689?cond=COVID-19&draw=2&rank=19

Condition or disease COVID-19

Drug: Dietary Supplement containing resistant starch – 197 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=resistant+starch+and+NLRP3

Dietary Supplement: Placebo Starch – 105 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=placebo+starch+and+NLRP3

Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19 (COVID-19)

https://clinicaltrials.gov/ct2/show/NCT04336462?cond=COVID-19&draw=2&rank=18

Condition or disease COVID-19

Device: oxyhydrogen – no papers

Device: Oxygen – 11,740 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=oxygen+and+NLRP3

Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia

https://clinicaltrials.gov/ct2/show/NCT04363346?cond=COVID-19&draw=2&rank=21

Condition or disease COVID-1

Drug: FT516 (NK cells) – 5,110 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=NK+cells+and+NLRP3

DAS181 for Severe COVID-19: Compassionate Use

https://clinicaltrials.gov/ct2/show/NCT04324489?cond=COVID-19&draw=2&rank=22

Condition or disease COVID-19

Drug: DAS181 – 10 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=DAS181+and+NLRP3

Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19 (ONSCOVID19)

https://clinicaltrials.gov/ct2/show/NCT04323228?cond=COVID-19&draw=2&rank=24

Condition or disease COVID-19

Dietary Supplement: oral nutrition supplement (ONS) enriched in

 – eicosapentaenoic acid, – 428 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=eicosapentaenoic+acid+and+NLRP3

 – gamma-linolenic acid and  – 178 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=gamma-linolenic+acid+and+NLRP3

 – antioxidants – 2,403 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=antioxidants+and+NLRP3

Study of Open Label Losartan in COVID-19

https://clinicaltrials.gov/ct2/show/NCT04335123?cond=COVID-19&draw=2&rank=27

Condition or disease COVID-19

Drug: Losartan – 206 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Losartan+and+NLRP3

Ivermectin and Nitazoxanide Combination Therapy for COVID-19

https://clinicaltrials.gov/ct2/show/NCT04360356?cond=COVID-19&draw=2&rank=29

Condition or disease COVID-19

Combination Product: Ivermectin – 58 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Ivermectin+and+NLRP3

plus Nitazoxanide – 28 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Nitazoxanide+and+NLRP3

Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19 (MATCH)

https://clinicaltrials.gov/ct2/show/NCT04370262?cond=COVID-19&draw=2&rank=30

Condition or disease COVID-19

Drug: HCQ – Hydroxychloroquine – 254 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Hydroxychloroquine+and+NLRP3

+ Intravenous Famotidine – 11 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Famotidine+and+NLRP3

Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19 (COVID-19)

https://clinicaltrials.gov/ct2/show/NCT04376788?cond=COVID-19&draw=2&rank=26

Condition or disease COVID-19

Biological: exchange blood transfusion from normal donor
Biological: plasma from convalescent patients with COVID-19
Drug: Methylene Blue 5 MG/ML – 282 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Methylene+Blue+and+NLRP3

A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection

https://clinicaltrials.gov/ct2/show/NCT04354831?cond=COVID-19&draw=2&rank=6

Condition or disease COVID-19

Biological: anti-SARS-CoV-2 convalescent plasma – 84 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=convalescent+plasma+and+NLRP3